MK2 Inhibition in CD4+ T Cells Protects Against IFNγ and IL-17A, Chronic Inflammation, and Fibrosis in Inflammatory Bowel Disease Models
Inflammatory Bowel Diseases · 13.06.2025 · 31 (6) · 1664-1676
DOI: 10.1093/ibd/izaf026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 12.02.2025. Verfasst von Cody S Howe und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Kentucky, Lexington, KY, USA. Hauptthemen laut MEDLINE: Interleukin-17, CD4-Positive T-Lymphocytes, Inflammatory Bowel Diseases, Interferon-gamma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Department of Defense Peer Reviewed Medical Investigator Awards, CCF Research Fellowship Award.
Abstract (Originalsprache)
Background
CD4+ T cells contribute to chronic inflammation and fibrosis in inflammatory bowel disease (IBD), but the cellular mechanisms remain elusive. We have found that the mitogen-activated protein kinase 2 (MK2) pathway plays a major role in inflammation and overall pathology in IBD. Thus, here, we examined the role of MK2 in regulating CD4+ T cell responses in IBD models.
Methods
Interleukin-10 (IL-10) knockout (KO) mice treated with MK2 inhibitors (MK2i) and CD4-specific MK2 knockdown mice treated with chronic dextran sodium sulfate (DSS) treatments were used to examine inflammation and fibrosis by multiplex array, gene expression, flow cytometry, and histology. Human tissues were treated with MK2i to examine Th1 and Th17 markers.
Results
IL-10 KO mice treated with MK2i therapeutically showed significantly reduced interferon gamma (IFNγ) and interleukin-17A (IL-17A) and a significantly reduced number of IFNγ+ and IL-17A+ producing CD4+ T cells by flow cytometry. To investigate the direct role of MK2 in CD4+ T cells during IBD, we utilized CD4-specific MK2 knockdown mice in chronic DSS colitis. A decrease in colonic inflammation, IFNγ and IL-17, pro-fibrotic genes, and extracellular matrix deposition was observed in mice with MK2 knockdown in CD4+ T cells compared to control mice. Additionally, IL-17A and IFNγ directly regulated the expression of fibrosis genes in colon tissues.
Conclusions
The MK2 pathway regulates inflammatory CD4+ T cells and fibrosis in IBD models and is a potential therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Kentucky, Lexington, KY, USA.
- Department of Medicine, Penn State College of Medicine, Hershey, PA, USA.
ORCID-Profile: Ellen J Beswick
Förderung
- NCI NIH HHS
- Department of Defense Peer Reviewed Medical Investigator Awards
- CCF Research Fellowship Award
Zitieren
APA
Howe, C. S., Chulkina, M., Syrcle, R., McAninch, C., McAninch, S., Pinchuk, I. V., & Beswick, E. J. (2025). MK2 Inhibition in CD4+ T Cells Protects Against IFNγ and IL-17A, Chronic Inflammation, and Fibrosis in Inflammatory Bowel Disease Models. Inflammatory Bowel Diseases, 31(6), 1664-1676. https://doi.org/10.1093/ibd/izaf026
Vancouver
Howe CS, Chulkina M, Syrcle R, McAninch C, McAninch S, Pinchuk IV, et al. MK2 Inhibition in CD4+ T Cells Protects Against IFNγ and IL-17A, Chronic Inflammation, and Fibrosis in Inflammatory Bowel Disease Models. Inflammatory Bowel Diseases. 2025;31(6):1664-1676. doi:10.1093/ibd/izaf026
BibTeX
@article{Howe2025,
author = {Howe, Cody S and Chulkina, Marina and Syrcle, Ryan and McAninch, Christina and McAninch, Steven and Pinchuk, Irina V and Beswick, Ellen J},
title = {MK2 Inhibition in CD4+ T Cells Protects Against IFNγ and IL-17A, Chronic Inflammation, and Fibrosis in Inflammatory Bowel Disease Models},
journal = {Inflammatory Bowel Diseases},
year = {2025},
volume = {31},
number = {6},
pages = {1664--1676},
doi = {10.1093/ibd/izaf026}
}
EUVIMED